Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous tumor cell vaccine in multiple myeloma
NCT00116441Phase 2Completed
- Sponsor
- Cell Genesys
- Start
- Oct 2000
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GVAX pancreatic cancer vaccine in multiple myeloma (MM), sponsored by Cell Genesys. Primary endpoint: Multiple myeloma. Started Oct 2000; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00116441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116441.